GlassScriptPhysician profile
Oleh Terleckyj
NPI 1144247958
$4,139.63
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,757 · 2020: $20.33 · 2021: $762 · 2022: $881 · 2023: $656 · 2024: $64.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $577.79 | 2019-2023 | |
| Abbvie INC. | $544.68 | 2019-2024 | Ubrelvy, Vraylar, Viberzi |
| Novo Nordisk INC | $507.88 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $305.46 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $272.24 | 2019-2022 | |
| Lilly USA, LLC | $240.72 | 2019-2023 | Mounjaro, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $187.62 | 2021-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $168.37 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.01 | 2019 | |
| Dexcom, INC. | $139.35 | 2021-2022 | |
| Amgen INC. | $137.24 | 2019-2022 | |
| Allergan, INC. | $103.09 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $93.79 | 2021 | |
| Abbott Laboratories | $87.99 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Dynavax Technologies Corporation | $83.33 | 2021-2023 | Heplisav-B |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $73.77 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $66.82 | 2019-2022 | |
| Astellas Pharma US INC | $65.68 | 2019 | |
| Bausch Health US, LLC | $53.54 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.61 | 2019-2023 | Xifaxan, Trulance |
| Ultragenyx Pharmaceutical INC. | $38.05 | 2021-2023 | |
| Depuy Synthes Sales INC. | $35.88 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.34 | 2022 | |
| Philips North America LLC | $19.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.19 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.00 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.50 | 2023 | Quviviq |
| Grifols USA, LLC | $13.61 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.94 | 2019 | |
| Hikma Pharmaceuticals USA | $12.26 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.26 | 2021 | |
| Biodelivery Sciences International, INC. | $11.85 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oleh Terleckyj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.